Children with underlying T1DM or T2DM who present in Diabetic Ketoacidosis will form the study population. Once diagnosed, the children will be categorized into moderate and severe diabetic ketoacidosis based on ISPAD 2022. An informed and written consent will be obtained from the parents of the child while an assent will also be taken in cases where the child is more than 8 years old. The consent and assent will be administered by the primary investigator (myself) or the pediatric intensive care fellow on duty. The enrolled subjects will be randomized using block randomization with pre-formed blocks of 4 with parallel arms. The intervention group will receive subcutaneous insulin glargine at a dose of 0.3units / kilogram within 2 hours of diagnosis of DKA followed by a same dose once every 24 hours while the control group will receive the standard treatment protocol. The brand of insulin glargine used will be Basalog (100 IU/ml) by Biocon limited. Both sets of patients will otherwise be managed with replacement fluids and insulin infusion as per ISPAD 2022 recommendations and any complications will be managed as per standard therapy. The lab monitoring for both groups will consist of an hourly bedside blood glucose level, venous blood gas every 6 hours and serum electrolytes and anion gap every 12 hours. On resolution of DKA (pH > 7.3 and HCO3 > 15), children in both groups will be transitioned to subcutaneous regular insulin as per the sliding scale  with continued monitoring of blood sugars and blood gas parameters additionally as indicated. An increase in BSL beyond  >250mg/dl within 2 hours after stopping of insulin infusion will be considered as rebound hyperglycemia. Demographical data, clinical data and laboratory findings of patients are recorded. Criteria considered to transfer the patient out of PICU include normalized glucose levels without any rebound hyperglycemia or acidosis, after 6 hours of transition from IV insulin infusion to subcutaneous (SC) insulin injections. The outcome measures will include time taken for acidosis resolution, total insulin infusion requirement, rate in fall of blood sugar level, incidence of complications (hypoglycemia / hypokalemia), incidence of rebound hyperglycemia and length of PICU stay.